Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan Drug Makers Join Trend Of Outsourcing Trials, Other Work

This article was originally published in PharmAsia News

Executive Summary

Japanese drug makers are joining the trend of outsourcing clinical trials to other countries. Daiichi Sankyo is moving its first trials to India beginning next month even though foreign tests cannot be used for drug approvals in Japan. But Daiichi Sankyo says trials are cheaper in India where the population is adopting Western eating habits, making them more suitable for drugs to be marketed in Western countries. Astellas Pharma plans trials in South Korea and Eisai is exporting clinical research work to Singapore and development in other Asian nations, particularly China and India. Smaller Japanese pharmas also are looking to join the trend. (Click here for more - a subscription may be required

You may also be interested in...

Japanese Pharma Looking Beyond Japan For Clinical Trials

TOKYO - Japanese pharmaceutical manufacturers are diversifying their Phase III clinical trials away from Japan to establish development footholds into fast-developing East Asia and other regions where costs are low and trial patients can be secured with ease

Asia Executives On The Move: Sanofi's Global R&D Head Moves To Innovent

Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.

Woodcock's Prophesy Comes True: US FDA ANDA Approvals Decline From Record Levels

Janet Woodcock’s 2019 prediction that record ANDA approval volumes would not continue is confirmed with the FY 2020 approval total down 21% from the previous year.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts